Submitted for Publication: August 11, 2014; final revision received November 4, 2014; accepted December 12, 2014.
Published Online: March 25, 2015. doi:10.1001/jamapsychiatry.2015.15.
Study concept and design: Roest, de Jonge, Schoevers, Turner.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Roest, de Jonge.
Critical revision of the manuscript for important intellectual content: de Jonge, Williams, de Vries, Schoevers, Turner.
Statistical analysis: Roest, Schoevers, Turner.
Obtained funding: Roest, de Jonge.
Administrative, technical, or material support: de Jonge, Williams, de Vries, Turner.
Study supervision: de Jonge, Williams, Schoevers, Turner.
Conflict of Interest Disclosures: Dr Schoevers received an unrestricted research grant as a coapplicant from Wyeth Pharmaceuticals, the Netherlands (2006) for a study comparing 2 forms of psychotherapy for major depressive disorder. From 1998 to 2001, Dr Turner served as a medical reviewer at the US Food and Drug Administration (FDA). From 2001 to 2005, Dr Turner provided outside consulting to Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. From 2004 to 2005, Dr Turner was on the speakers bureaus of AstraZeneca, Bristol-Myers Squibb, and Eli Lilly. No other disclosures were reported.
Funding/Support: This study was supported by grant KS2011(1)-120 from the Dutch Brain Foundation (Dr de Jonge).
Role of the Funder/Sponsor: The Dutch Brain Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Jay Augsberger, MD, Department of Veterans Affairs, assisted in obtaining FDA Drug Approval Packages from the FDA’s Freedom of Information Office; he received no financial compensation.